Sodium-Glucose CoTransporter-2 Inhibitor Empagliflozin Ameliorates Sunitinib-Induced Cardiac Dysfunction via Regulation of AMPK-mTOR Signaling Pathway-Mediated Autophagy

• Главные авторы: Changzhen Ren (Автор), Kaiqiang Sun (Автор), Yanda Zhang (Автор), Yangxi Hu (Автор), Bowen Hu (Автор), Jian Zhao (Автор), Zhiqing He (Автор), Ru Ding (Автор), Weizhong Wang (Автор), Chun Liang (Автор)
• Формат: ‌
• Опубликовано: Frontiers Media S.A., 2021-04-01T00:00:00Z.
• Предметы: article
• Online-ссылка: Connect to this object online.

Background: Sodium-glucose cotransporter-2 (SGLT2) inhibitors have been shown to decrease the adverse cardiac events and risks of cardiovascular mortality among patients with or without diabetes, which has made these drugs promising treatment options for patients with chronic heart failure. Cardiac...